文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers.

作者信息

Tsao Shiu Ying

机构信息

Department of Clinical Research, Hong Kong SAR Oncology Centre, Hong Kong SAR 999077, China.

出版信息

Explor Target Antitumor Ther. 2022;3(5):676-693. doi: 10.37349/etat.2022.00107. Epub 2022 Oct 31.


DOI:10.37349/etat.2022.00107
PMID:36338522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9630551/
Abstract

In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant. Of the ways of patching up such deficits, chemotherapy (ChT), especially if metronomic, seems promising, especially as immunity induced by immunogenic cell death (ICD) may be preserved. However, side effects, e.g., lymphocytopenia and interstitial pneumonitis cannot be ignored; eventually, resistance may also ensue. Vascular endothelial growth factors (VEGFs), being potent angiogenic factors, promote cancer cells' purposeful angiogenesis rendering an extremely resistant tumor microenvironment (TME). This highly evasive and extremely resilient TME actually demands multi-agent, multi-target agents as currently in use through traditional Chinese medicine (TCM). With a good track record of 3,000 years, TCM is favored by mainland Chinese cancer patients. Although TCM had been criticized as unscientific and imprecise, recently, artificial intelligence (AI) technologies serve to elucidate the sound scientific basis and validity of TCM. Several TCM preparations having anti-VEGF actions are found; others suppress immune checkpoints. Especially, these herbs' multi-prong approach appears to be more effective than Western medicine's primarily monotherapy approach if one wishes to eradicate the very resistant TME. A "bonus" point is that some autoimmune-related adverse side effects of ICBs may also be reduced by TCM. Nevertheless, as the TCM experience is mostly anecdotal, robust clinical trials are mandatory. Moreover, other TCM problems, e.g., herbal batch variations and consistency and uniformity of herbal prescriptions are outstanding. Invariably, TCM prescriptions have daily variations as the practice of "syndrome differentiation" is hailed. Despite experienced TCM practitioners would refuse to give up their time-honored traditional practice, the multi-prong approach is still very attractive for the undue resilience of TME, let alone its good safety profile, ready availability, and eminent affordability. Although the passage is dark, light is now appearing at the end of the tunnel.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/b5002fd5f676/etat-03-1002107-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/5b289edfc718/etat-03-1002107-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/495bb7f8fe0d/etat-03-1002107-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/b5002fd5f676/etat-03-1002107-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/5b289edfc718/etat-03-1002107-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/495bb7f8fe0d/etat-03-1002107-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c54f/9630551/b5002fd5f676/etat-03-1002107-g003.jpg

相似文献

[1]
Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers.

Explor Target Antitumor Ther. 2022

[2]
Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery.

Curr Top Med Chem. 2020

[3]
Progress in the Regulation of Immune Cells in the Tumor Microenvironment by Bioactive Compounds of Traditional Chinese Medicine.

Molecules. 2024-5-17

[4]
Usefulness of traditionally defined herbal properties for distinguishing prescriptions of traditional Chinese medicine from non-prescription recipes.

J Ethnopharmacol. 2007-1-3

[5]
Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.

J Ethnopharmacol. 2020-4-6

[6]
Impact of TCM on Tumor-Infiltrating Myeloid Precursors in the Tumor Microenvironment.

Front Cell Dev Biol. 2021-3-4

[7]
Opportunities and challenges of traditional Chinese medicine doctors in the era of artificial intelligence.

Front Med (Lausanne). 2024-1-11

[8]
Antitumor effects of immunity-enhancing traditional Chinese medicine.

Biomed Pharmacother. 2019-11-9

[9]
Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation.

Br J Pharmacol. 2006-12

[10]
The Effectiveness of Traditional Chinese Medicine in Treating Malignancies via Regulatory Cell Death Pathways and the Tumor Immune Microenvironment: A Review of Recent Advances.

Am J Chin Med. 2024

引用本文的文献

[1]
Focus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer.

Chin Med. 2023-6-24

[2]
Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions.

Chin Med. 2023-5-20

本文引用的文献

[1]
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Lancet Oncol. 2022-7

[2]
The Use of Artificial Intelligence in Complementary and Alternative Medicine: A Systematic Scoping Review.

Front Pharmacol. 2022-4-1

[3]
Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.

J Oncol. 2022-2-22

[4]
DNA topoisomerase inhibition with the HIF inhibitor acriflavine promotes transcription of lncRNAs in endothelial cells.

Mol Ther Nucleic Acids. 2022-1-25

[5]
Traditional Chinese Medicine Pien-Tze-Huang Inhibits Colorectal Cancer Growth and Immune Evasion by Reducing β-catenin Transcriptional Activity and PD-L1 Expression.

Front Pharmacol. 2022-2-3

[6]
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

J Immunother Cancer. 2022-1

[7]
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.

Cancer Treat Rev. 2022-2

[8]
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.

Thorac Cancer. 2022-2

[9]
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

J Hepatol. 2022-4

[10]
What do cellular responses to acidity tell us about cancer?

Cancer Metastasis Rev. 2021-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索